Gemcitabine

目录号:S1714 别名: LY-188011, NSC 613327

Gemcitabine  Chemical Structure

Molecular Weight(MW): 263.2

Gemcitabine是核酸合成抑制剂,是有效、特异的脱氧胞苷类似物,用于化疗。

规格 价格 库存 购买数量  
RMB 1057.63 现货
RMB 782.86 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献21篇:

客户使用该产品的5个实验数据:

  • RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck.

    Mice were administered either vehicle, gemcitabine (120 mg/kg [PaCa2]) or 20 mg/kg of BBI608 i.p. After killing, tumors were collected after 7 or 14 d of treatment, for Paca-2 and FaDu cells, respectively. Single-cell suspensions were obtained after animal killing and sterile removal of tumors. Live cells were then counted and used to measure their ability to form spheres when cultured in cancer stem cell media.

    Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck.

  • a: KMBC (blue circles) and HuCCT1 (purple squares) cells were plated in 384-well plates (1,000 cells/well), and incubated with varying concentrations of gemcitabine. Cell viability was assessed after 72 h using Cell Titer GloR 2.0 assay. Data represents the average percent cell viability plotted against concentration of drug in nM from 4 replicates for each condition.

    Mol Cancer, 2017, 16(1):22. Gemcitabine purchased from Selleck.

    Immunofluorescent analysis of gemcitabine-induced γH2A.X and 53-BP1 focus formation. a, b Immunofluorescence staining of γH2A.X(green), 53-BP1 (red), and nuclei staining with DAPI (blue) in T24 (a) and T24r GEMCI20 (b) cells after the indicated treatments. Scale bar = 50 μm

    J Exp Clin Cancer Res, 2017, 36(1):1. Gemcitabine purchased from Selleck.

  • Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.

    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck.

产品安全说明书

DNA/RNA Synthesis抑制剂选择性比较

生物活性

产品描述 Gemcitabine是核酸合成抑制剂,是有效、特异的脱氧胞苷类似物,用于化疗。
体外研究

在CCRF-CEM人白血病细胞培养物中,Gemcitabine抑制50%的细胞生长,IC50为1 纳克/毫升。Gemcitabine和deoxycytidine联用使生物活性降低1000倍。[1] 在人胰腺癌L3.6pl细胞中,Gemcitabine和C225联用产生额外的细胞毒作用,并随Gemcitabine浓度增多而增强。[2] 在野生型A2780和耐顺铂ADDP细胞中,Gemcitabine和Cisplatin联用产生协同效应。 [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 M1XJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2f1XWlEPTB;MD6wNFA1PThibl2= NHmzUnBUSU6JRWK=
ES4 NHf1SYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoSxTWM2OD1yLkCwNFY2OyCwTR?= M1PrOHNCVkeHUh?=
ACHN MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[0NVFKSzVyPUCuNFAxQDh5IH7N NWXFNYt[W0GQR1XS
KYSE-510 M4PQVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;LTWM2OD1yLkCwNFk4PSCwTR?= MYfTRW5ITVJ?
EW-7 NXvGemhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fHcmlEPTB;MD6wNFI2QCCwTR?= Mn7nV2FPT0WU
BFTC-905 NY\MPYFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;WSWZEUUN3ME2wMlAxPTF3IH7N M{jj[nNCVkeHUh?=
KE-37 MmmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzDTWM2OD1yLkCwOVYyKG6P MUTTRW5ITVJ?
SBC-5 M{L1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFj0TmFKSzVyPUCuNFA2PyCwTR?= NXroVXk6W0GQR1XS
NKM-1 Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT0dI9KSzVyPUCuNFA4ODlibl2= NH\6N3NUSU6JRWK=
RH-1 NYHhcI1GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzxTWM2OD1yLkCwO|E5KG6P NIrhXWRUSU6JRWK=
ALL-PO MmfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwMEC4N{BvVQ>? NEC0bZJUSU6JRWK=
QIMR-WIL MmrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwMEC4PVQhdk1? M1TQXHNCVkeHUh?=
A375 M1HLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwMEC5PVUhdk1? MYrTRW5ITVJ?
SIG-M5 Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;NTWM2OD1yLkCxNFQhdk1? MoDuV2FPT0WU
KGN NHXIW5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\HcGlEPTB;MD6wNVA5KG6P MkPuV2FPT0WU
EW-13 M{HUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMEGxNkBvVQ>? MYHTRW5ITVJ?
NCI-SNU-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfIWGpCUUN3ME2wMlAyPiCwTR?= MojkV2FPT0WU
PSN1 MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmj3TWM2OD1yLkCxOlUhdk1? MmfYV2FPT0WU
HUTU-80 NInrb3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jaeWlEPTB;MD6wNVY3KG6P MmHrV2FPT0WU
EW-16 MoWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwMEKzJI5O MlHVV2FPT0WU
786-0 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMEKzJI5O M{LzW3NCVkeHUh?=
ES1 M3niU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7UTVhKSzVyPUCuNFI3QCCwTR?= MnvoV2FPT0WU
RKO NVnVNG1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfESZZKSzVyPUCuNFI4QSCwTR?= M4rofHNCVkeHUh?=
ESS-1 MnSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;2TWM2OD1yLkCyPFYhdk1? NHO5XGNUSU6JRWK=
SK-UT-1 NVHoOpd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjQfnBPUUN3ME2wMlAzQTdibl2= NIDjWlJUSU6JRWK=
LB2241-RCC M{nLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DBfmlEPTB;MD6wN|E5KG6P MU\TRW5ITVJ?
CHL-1 NIG5b|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrDUmFKSzVyPUCuNFMzPCCwTR?= NWn1VoZHW0GQR1XS
SW1783 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7VRVR[UUN3ME2wMlA{OzZibl2= NFXZdGNUSU6JRWK=
MEL-JUSO MnPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3S4ZmlEPTB;MD6wN|kyKG6P NFT1[41USU6JRWK=
HT-29 NInBd4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1X2e2lEPTB;MD6wOFE{KG6P M2\BWHNCVkeHUh?=
SNG-M MlTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHpWYk6UUN3ME2wMlA1OjVibl2= NH;NW|BUSU6JRWK=
TE-15 MoTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;IOW5xUUN3ME2wMlA1PjRibl2= NVTEOnQ1W0GQR1XS
HOS M3u0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1e0VmlEPTB;MD6wOFghdk1? M2rmUnNCVkeHUh?=
BB65-RCC M2TFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjsTWM2OD1yLkC1NVIhdk1? M{\hSnNCVkeHUh?=
HCE-4 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvjZYh5UUN3ME2wMlA2Ojhibl2= NGPaNGxUSU6JRWK=
MHH-ES-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwMEWzNUBvVQ>? MVrTRW5ITVJ?
RPMI-7951 NFvvZWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;yPYFZUUN3ME2wMlA2PDFibl2= NYLr[I9nW0GQR1XS
IST-SL2 MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzUTWM2OD1yLkC1PFQhdk1? NU\4Z3c4W0GQR1XS
CMK NV7LWFZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHv4XmxKSzVyPUCuNFU5PiCwTR?= Ml;XV2FPT0WU
GR-ST NEKwZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7qTWM2OD1yLkC1PVUhdk1? NHTM[XlUSU6JRWK=
NALM-6 NE\vZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwME[yNkBvVQ>? M3nR[HNCVkeHUh?=
RPMI-6666 M2PoW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnlT4xKSzVyPUCuNFY2OiCwTR?= MnywV2FPT0WU
LC-2-ad NHLDPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nqVmlEPTB;MD6wOlU{KG6P NGToTolUSU6JRWK=
ARH-77 MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHL5dolKSzVyPUCuNFcyOSCwTR?= NXjYT3V6W0GQR1XS
IST-MEL1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7MR3dkUUN3ME2wMlA4OjZibl2= MoK1V2FPT0WU
SW1710 NUe0epBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMEe1NUBvVQ>? MWHTRW5ITVJ?
DEL Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{npU2lEPTB;MD6wPFg4KG6P MXnTRW5ITVJ?
AGS MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17TUWlEPTB;MD6wPVAzKG6P M3G2S3NCVkeHUh?=
NCI-H2122 MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVmyZYxHUUN3ME2wMlA6PDZibl2= M1P3b3NCVkeHUh?=
HSC-4 M{nHOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjlfpJKSzVyPUCuNVAzKG6P MXLTRW5ITVJ?
AM-38 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWWwVZVyUUN3ME2wMlEzOSCwTR?= NFzYdYJUSU6JRWK=
769-P M2TkPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7BcpRKSzVyPUCuNVI{KG6P MlfRV2FPT0WU
RT-112 NFLXXmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwMUK3JI5O NGTESHVUSU6JRWK=
MCF7 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL4WWxTUUN3ME2wMlE{PiCwTR?= MVnTRW5ITVJ?
IGROV-1 NVX0bHF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfqUnlQUUN3ME2wMlE1PSCwTR?= M1Tje3NCVkeHUh?=
OCI-AML2 NUjLelNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\QUm1FUUN3ME2wMlE1PyCwTR?= M2K5d3NCVkeHUh?=
NCI-H1299 M2DtVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vwSWlEPTB;MD6xOVchdk1? NULRVXRZW0GQR1XS
A431 NGPBXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGm3NHZKSzVyPUCuNVg{KG6P M2DqfnNCVkeHUh?=
SW982 NWn1bpZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLO[ZFKSzVyPUCuNlE{KG6P M2fPPHNCVkeHUh?=
BB30-HNC NE\XcY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMkOxJI5O M{TPdnNCVkeHUh?=
ACN M36yPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkmzTWM2OD1yLkK0OEBvVQ>? NX7uUWJLW0GQR1XS
647-V M{jvZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XpUmlEPTB;MD6yOFghdk1? M2C3cXNCVkeHUh?=
SK-PN-DW M{izcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHMPVhKSzVyPUCuNlY3KG6P MWrTRW5ITVJ?
LCLC-97TM1 NFHze5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvPdXVKSzVyPUCuNlY4KG6P M3TJVHNCVkeHUh?=
LB1047-RCC NX;k[XNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2SwbGlEPTB;MD6yOlkhdk1? MYPTRW5ITVJ?
A2780 MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwMkegcm0> MlzYV2FPT0WU
C-33-A MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnmTWM2OD1yLkK3N{BvVQ>? NVXHenNwW0GQR1XS
NCI-H2228 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\sbVVJUUN3ME2wMlMyPCCwTR?= MofnV2FPT0WU
TE-5 NX3IZXdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjxN4FKSzVyPUCuN|E3KG6P M33zXnNCVkeHUh?=
HC-1 NYnuVVRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwM{K3JI5O MlLVV2FPT0WU
SK-MES-1 NFzabo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7KVYY5UUN3ME2wMlMzQCCwTR?= Mk\lV2FPT0WU
NCI-H1355 M3T5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvGbVhqUUN3ME2wMlM5OSCwTR?= M2DidXNCVkeHUh?=
YKG-1 MmjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn30TWM2OD1yLkSxPUBvVQ>? NE[3dm5USU6JRWK=
RS4-11 NEL1V45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwNEOzJI5O NYDZSZlqW0GQR1XS
Daoy MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHVTWM2OD1yLkS1OkBvVQ>? NHfpOWpUSU6JRWK=
A3-KAW M4C0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXmNmt6UUN3ME2wMlU2OSCwTR?= MVfTRW5ITVJ?
SK-MEL-30 NGPaTm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HlWGlEPTB;MD61OVQhdk1? NETOZ|dUSU6JRWK=
U031 MnrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLqTWM2OD1yLkW2OUBvVQ>? NFPoXHpUSU6JRWK=
SK-LMS-1 MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYey[|lpUUN3ME2wMlU4QCCwTR?= MnXSV2FPT0WU
ES6 NI\KUYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwNUi2JI5O NG\v[3FUSU6JRWK=
EoL-1-cell MnvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwNkG2JI5O MYHTRW5ITVJ?
NCI-H2009 NFK2Zm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HkUmlEPTB;MD62NVkhdk1? NGjJWWJUSU6JRWK=
A4-Fuk Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETZRo9KSzVyPUCuOlI3KG6P MWLTRW5ITVJ?
KYSE-270 NYn6T4NOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwNkO0JI5O MmX2V2FPT0WU
SK-LU-1 NIe4[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwNkW1JI5O NYTL[Y5KW0GQR1XS
SW872 M4jTWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTFTWM2OD1yLke2OUBvVQ>? NH:0ZYxUSU6JRWK=
ES8 M2TBWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnLb2lKSzVyPUCuO|ghdk1? MY\TRW5ITVJ?
G-402 M4q1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[yelhKSzVyPUCuO|g1KG6P MlO5V2FPT0WU
ATN-1 Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF33S2xKSzVyPUCuPFA4KG6P NH3jPJJUSU6JRWK=
DoTc2-4510 NH\PN25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwOUCxJI5O Mn\iV2FPT0WU
MES-SA Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwOUC1JI5O NYLuOmpQW0GQR1XS
SF268 NYHtPXpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjibXlpUUN3ME2wMlkzPyCwTR?= NFm0fpVUSU6JRWK=
SF539 MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjYNoRrUUN3ME2xMlAzKG6P MX7TRW5ITVJ?
NB69 M1r4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rLT2lEPTB;MT6wOUBvVQ>? M3;yUXNCVkeHUh?=
8505C NFLZUFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NECxfnpKSzVyPUGuNFYhdk1? MkXmV2FPT0WU
CAL-12T NWOwWm5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWToUFM3UUN3ME2xMlA5KG6P NYPMSVVtW0GQR1XS
BHY NH;KUFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjmd3hKSzVyPUGuNVQhdk1? NF;hZ|FUSU6JRWK=
LB647-SCLC Mn;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\JVmlEPTB;MT6xPEBvVQ>? MoqxV2FPT0WU
CAL-62 NILiZ2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\PNlBvUUN3ME2xMlIzKG6P M2rZV3NCVkeHUh?=
MEG-01 NIPJ[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfQZ41uUUN3ME2xMlI4KG6P MWTTRW5ITVJ?
MG-63 NULRXIpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDq[ZhQUUN3ME2xMlM{KG6P MXzTRW5ITVJ?
SW620 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXOdZc3UUN3ME2xMlM2KG6P M{i0N3NCVkeHUh?=
A388 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTFwM{[gcm0> MlPtV2FPT0WU
BCPAP MknxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLxUZFnUUN3ME2xMlQ2KG6P NX\UfpJ4W0GQR1XS
P30-OHK M4jVVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTFwNE[gcm0> MXfTRW5ITVJ?
Ca9-22 Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTFwNUSgcm0> MonQV2FPT0WU
VMRC-RCZ M1nmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vYPWlEPTB;MT61OEBvVQ>? M2PqVXNCVkeHUh?=
LOXIMVI NH;VSnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTFwNjDuUS=> NVHCO5JEW0GQR1XS
L-540 M3;nXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7oSI1KSzVyPUGuOkBvVQ>? MYTTRW5ITVJ?
NTERA-S-cl-D1 Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFwNkSgcm0> NEnPZ|ZUSU6JRWK=
MFH-ino NH3sVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrFO5BKSzVyPUGuOlYhdk1? MXXTRW5ITVJ?
Calu-6 NV\CVXhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL6c3pKSzVyPUGuO|Mhdk1? MV;TRW5ITVJ?
HEL M3;ybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfCTWM2OD1zLke5JI5O MlflV2FPT0WU
CAL-33 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHPfI5KSzVyPUGuPFkhdk1? MVfTRW5ITVJ?
HSC-3 M2LVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTFwOUGgcm0> MoHDV2FPT0WU
KU812 MoTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXUdVJxUUN3ME2xMlkyKG6P M37NVXNCVkeHUh?=
EB2 MlzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\FTWM2OD1{LkCxJI5O M4XuWHNCVkeHUh?=
SR NWXvbXpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmriTWM2OD1{LkGyJI5O MWPTRW5ITVJ?
NCI-H2087 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnFTWM2OD1{LkG0JI5O MYDTRW5ITVJ?
H4 MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\KfnNEUUN3ME2yMlE5KG6P NYG5NIFHW0GQR1XS
EW-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH74U|dKSzVyPUKuNlIhdk1? NUL5W5ZXW0GQR1XS
MC-IXC NWXMVIFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjnc4pMUUN3ME2yMlI3KG6P M2f4VHNCVkeHUh?=
NCI-H727 NUXIfVdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXNTWM2OD1{LkWxJI5O MXvTRW5ITVJ?
MRK-nu-1 NWDqWIxqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGT6e2tKSzVyPUKuOVchdk1? M{HhRXNCVkeHUh?=
COLO-668 NFr3VnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3tRXRKSzVyPUKuOlYhdk1? NXrJTXVNW0GQR1XS
CGTH-W-1 M3TNT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTJwN{Kgcm0> NFvne4FUSU6JRWK=
CHP-212 MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDCW29rUUN3ME2yMlc2KG6P MX7TRW5ITVJ?
GI-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4P1W2lEPTB;Mj63OkBvVQ>? MVfTRW5ITVJ?
HCC1806 NXOzNXFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33jOGlEPTB;Mj65NUBvVQ>? NFL5XVlUSU6JRWK=
HLE NHvHT|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTKTWM2OD1|IH7N NI\mZmZUSU6JRWK=
HSC-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHzU4ZKSzVyPUOuNFMhdk1? MWPTRW5ITVJ?
DMS-273 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1P3S2lEPTB;Mz6wO{BvVQ>? MXvTRW5ITVJ?
DU-4475 NXrkfI81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTNwMUSgcm0> NIfJWYpUSU6JRWK=
LXF-289 M{GwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXT[FZKSzVyPUOuN|Ehdk1? NIHWbXhUSU6JRWK=
PANC-03-27 NVe3UZV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTNwNUGgcm0> MkDRV2FPT0WU
GAMG M4HRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHPUYFKSzVyPUOuO|Qhdk1? NXjScXlZW0GQR1XS
NCI-H522 MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL5e2tJUUN3ME20MlM1KG6P MYTTRW5ITVJ?
SW626 NHnKfpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXNNpNKSzVyPUSuOFYhdk1? M1TwVHNCVkeHUh?=
HT-144 M4qwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTRwOUKgcm0> MlHMV2FPT0WU
MEL-HO M4XpNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTVwMU[gcm0> MlSyV2FPT0WU
BE-13 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfNSFFKSzVyPUWuNlEhdk1? M2HIUnNCVkeHUh?=
VA-ES-BJ NYLJWZJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnp[FRlUUN3ME21MlI3KG6P MljIV2FPT0WU
NCI-H441 M1;BT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nX[GlEPTB;NT62JI5O MYnTRW5ITVJ?
KP-4 M1foSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrzVIdxUUN3ME21MlYyKG6P MX3TRW5ITVJ?
LoVo MnraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37jNWlEPTB;NT63NUBvVQ>? NFX2NoNUSU6JRWK=
HT-1080 MoH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknkTWM2OD13LkizJI5O MnjJV2FPT0WU
GB-1 M3jYe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrYcXpwUUN3ME21Mlg1KG6P MlPQV2FPT0WU
IA-LM NEnQW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LK[WlEPTB;NT65NUBvVQ>? NIDQVVBUSU6JRWK=
8-MG-BA Mm\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TYemlEPTB;NT65N{BvVQ>? M2X0VnNCVkeHUh?=
SK-HEP-1 M131e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzHTWM2OD14LkG0JI5O NF\5cmlUSU6JRWK=
697 M2f5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1W3bWlEPTB;Nj6yOUBvVQ>? MnzTV2FPT0WU
KYSE-450 NFjTWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1O1U2lEPTB;Nj6zNkBvVQ>? MVLTRW5ITVJ?
HCC2998 NGe3SG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkS5TWM2OD14LkO0JI5O NXu5Omp{W0GQR1XS
HD-MY-Z M2\2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTDTWM2OD14Lk[4JI5O NGDMU29USU6JRWK=
OS-RC-2 M4ezU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTZwNkigcm0> M3q0enNCVkeHUh?=
SF126 M1fCR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH73eWpKSzVyPUeuNFUhdk1? Mmr2V2FPT0WU
Ca-Ski MnTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnewTWM2OD15LkC5JI5O Mn3SV2FPT0WU
NCI-H358 NU\0UWJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfvSG5KSzVyPUeuNVYhdk1? MVHTRW5ITVJ?
J82 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\sTWM2OD15LkSxJI5O MkPrV2FPT0WU
NCI-H2342 NIP5e41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHnUnU{UUN3ME23MlY{KG6P MWnTRW5ITVJ?
OVCAR-8 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj1TWM2OD15Lkmgcm0> MUfTRW5ITVJ?
TE-8 M2\zOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfUZnQ5UUN3ME24JI5O MojzV2FPT0WU
ETK-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;mS4p7UUN3ME24MlA5KG6P NHHhfJZUSU6JRWK=
HAL-01 NX3WdIlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFG0WJpKSzVyPUiuNkBvVQ>? MV\TRW5ITVJ?
KYSE-150 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrHcGhKSzVyPUiuOFchdk1? MmnmV2FPT0WU
NCI-H810 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzK[mdXUUN3ME24MlU3KG6P NH[xZmFUSU6JRWK=
ONS-76 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRThwNkigcm0> MXTTRW5ITVJ?
NMC-G1 NF3RR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\YXXpKSzVyPUiuO|Yhdk1? NV;LcIpbW0GQR1XS
C3A MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TMbGlEPTB;OD64OEBvVQ>? NWq5XmkyW0GQR1XS
PA-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrqTWM2OD16Lkm5JI5O M3OxfHNCVkeHUh?=
SH-4 NFe2NIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTlwMEKgcm0> MmLQV2FPT0WU
EFO-27 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHUTWM2OD17LkC1JI5O MmXTV2FPT0WU
CAPAN-1 NX\sU2VuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGmxepdKSzVyPUmuNlMhdk1? NYK4T4JUW0GQR1XS
DU-145 NHnNRmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXLTWM2OD17LkK5JI5O MXfTRW5ITVJ?
A101D NH\TNGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTlwM{egcm0> MWDTRW5ITVJ?
ST486 M1;zWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEX0eWJKSzVyPUmuOFEhdk1? M{fDPXNCVkeHUh?=
NCI-H1437 NGnBXYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfwSlQxUUN3ME25MlQzKG6P MljKV2FPT0WU
HGC-27 MkD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLnVGxKSzVyPUmuOkBvVQ>? MWnTRW5ITVJ?
8305C MoD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjCTWM2OD17Lk[0JI5O M33ON3NCVkeHUh?=
OCUB-M NIrZRpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PFeWlEPTB;MUCuNFMhdk1? MnjkV2FPT0WU
COLO-679 MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPUPHl1UUN3ME2xNE4xPyCwTR?= NIDyVlVUSU6JRWK=
Detroit562 M4nhNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTV[VFKSzVyPUGwMlQzKG6P MXLTRW5ITVJ?
A204 NEPxTlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTFzLkG2JI5O MonRV2FPT0WU
NCI-H1734 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIS4clRKSzVyPUGxMlI6KG6P Ml61V2FPT0WU
MC-CAR M33EUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVuzNIpOUUN3ME2xNU42QCCwTR?= NXLxXm5sW0GQR1XS
NCI-H2170 NYnTeFJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPwfHFnUUN3ME2xNU46PyCwTR?= NVHNb4piW0GQR1XS
NCI-SNU-5 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTF{LkGzJI5O NH[3dZhUSU6JRWK=
HCE-T Mn7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHzTWM2OD1zMj60NkBvVQ>? MXTTRW5ITVJ?
KYSE-180 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3xTWM2OD1zMj64NUBvVQ>? NFXzfJBUSU6JRWK=
C8166 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTF|LkC4JI5O NFy3eVNUSU6JRWK=
NCI-H460 NHfRTGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3SzWGlEPTB;MUOuOVQhdk1? MlzlV2FPT0WU
SNU-449 NUHZcVVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2W0W2lEPTB;MUOuO|chdk1? NVrKe5FwW0GQR1XS
MDA-MB-468 NGGyOlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ryW2lEPTB;MUSuNVIhdk1? MmjoV2FPT0WU
COR-L23 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmS0TWM2OD1zND6xN{BvVQ>? M3HmVXNCVkeHUh?=
CTV-1 NEC3N3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3ETWM2OD1zND6xOEBvVQ>? MXrTRW5ITVJ?
BL-41 M36xcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzXTWM2OD1zND6zO{BvVQ>? MUfTRW5ITVJ?
IGR-1 M3jzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LpPGlEPTB;MUSuOFIhdk1? NIfBOGpUSU6JRWK=
TK10 NHy5cmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrMTWM2OD1zND60PUBvVQ>? M4LFeHNCVkeHUh?=
REH NXzrWYJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPVTWM2OD1zND61NUBvVQ>? M{LnXHNCVkeHUh?=
LU-139 Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rrc2lEPTB;MUSuOVkhdk1? MkXFV2FPT0WU
KP-N-YS NH7rVFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn6TWM2OD1zND65O{BvVQ>? NX;ZdmJsW0GQR1XS
PANC-10-05 NHHISHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTF3LkO4JI5O M2\4UHNCVkeHUh?=
HL-60 M3PpPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHyTWM2OD1zNT62PUBvVQ>? MVTTRW5ITVJ?
T84 NXqxVZZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXXTWM2OD1zNT65OkBvVQ>? MkH6V2FPT0WU
RPMI-8226 MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HnOGlEPTB;MU[uNFIhdk1? NF\lZopUSU6JRWK=
UM-UC-3 NYXKbnVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7PTWM2OD1zNj6xOkBvVQ>? MV7TRW5ITVJ?
TE-10 M1ToWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTF4LkKxJI5O M{CyTHNCVkeHUh?=
CAL-148 MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;GTWM2OD1zNz6yN{BvVQ>? NHe4fFNUSU6JRWK=
BV-173 NVvIXmhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTF5LkK3JI5O MnTEV2FPT0WU
Calu-3 NXHMdmdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjlPIR2UUN3ME2xO{4zQSCwTR?= MWPTRW5ITVJ?
RPMI-2650 NHfOTY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fPfmlEPTB;MUeuOVkhdk1? NULDd|RbW0GQR1XS
MKN45 NVq1XG5vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfCN2JKSzVyPUG3Mlc{KG6P NVTvR2NUW0GQR1XS
NUGC-3 NHS0[mFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTF6LkO0JI5O NGC2fodUSU6JRWK=
NCI-H520 M3fyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rz[2lEPTB;MUiuO|chdk1? MnPNV2FPT0WU
CCRF-CEM NV20bZB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PlRWlEPTB;MUiuPFUhdk1? MX7TRW5ITVJ?
NCI-H2405 NUPBe3lvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTF7LkGgcm0> MUnTRW5ITVJ?
ES7 M3\kWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTF7Lke2JI5O M{DOUHNCVkeHUh?=
BPH-1 M1HOOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTMTWM2OD1{MD6yPEBvVQ>? NUL3c4pjW0GQR1XS
SAS NI\kNodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;odZE4UUN3ME2yNE42KG6P NIKyVm5USU6JRWK=
HuCCT1 M3q5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Xhc2lEPTB;MkCuOVghdk1? MnXTV2FPT0WU
LOUCY M1GxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4T2NGlEPTB;MkCuOlYhdk1? NFvhTW5USU6JRWK=
NCI-H292 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[1fGlKSzVyPUKwMlc6KG6P M4PVdnNCVkeHUh?=
G-361 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPhcoU{UUN3ME2yNU4xPyCwTR?= MV;TRW5ITVJ?
M059J MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLsTWM2OD1{MT6wPEBvVQ>? NWH3XoJbW0GQR1XS
NCI-H1651 MmDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTJzLkGxJI5O NHj5eZhUSU6JRWK=
KALS-1 Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmH2TWM2OD1{MT6zPUBvVQ>? NWL2dFY6W0GQR1XS
DJM-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPETWM2OD1{MT61PUBvVQ>? M{PKbXNCVkeHUh?=
AU565 MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L1UmlEPTB;MkGuPFMhdk1? MVvTRW5ITVJ?
HCC38 M4CwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPhTWM2OD1{MT65OUBvVQ>? NWLxRWJPW0GQR1XS
U251 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnTVGVKSzVyPUKyMlI4KG6P Mk\QV2FPT0WU
ABC-1 MoHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PTR2lEPTB;MkKuOlUhdk1? MnTBV2FPT0WU
SK-NEP-1 NVfEPWlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDoNotKSzVyPUKyMlk{KG6P M2Dsd3NCVkeHUh?=
CESS NXToSogyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fWfmlEPTB;MkOuNVkhdk1? MW\TRW5ITVJ?
MIA-PaCa-2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjYRoUzUUN3ME2yN{4{PiCwTR?= MX7TRW5ITVJ?
SUP-T1 M3S3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjRTWM2OD1{Mz60O{BvVQ>? MmnLV2FPT0WU
L-428 NWDyXW03T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7NXYQ1UUN3ME2yN{43OiCwTR?= MnPuV2FPT0WU
SW954 NWTDT5JCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTXPYlYUUN3ME2yN{43QCCwTR?= NYnOR|BbW0GQR1XS
HO-1-N-1 NIT6ZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHn1bmlKSzVyPUKzMlc4KG6P MlXIV2FPT0WU
CHP-126 MkTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfRS4x[UUN3ME2yOE4yPCCwTR?= MXHTRW5ITVJ?
HMV-II NYHBb2FiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTJ2LkO0JI5O MlHwV2FPT0WU
NB10 M1nZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nlR2lEPTB;MkSuN|chdk1? MV3TRW5ITVJ?
A172 Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\Pe3pDUUN3ME2yOE44OSCwTR?= M1HF[nNCVkeHUh?=
MONO-MAC-6 M1mySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TQbmlEPTB;MkSuPFQhdk1? Mo\hV2FPT0WU
NCI-H1650 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILwd5dKSzVyPUK1MlQhdk1? NF\oe4JUSU6JRWK=
NH-12 NGTTXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPzXFFUUUN3ME2yOU42KG6P NHHpd49USU6JRWK=
ML-2 NUXuPXR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrZPWVKSzVyPUK1Mlc1KG6P M2jMSnNCVkeHUh?=
MZ2-MEL MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLJZWx5UUN3ME2yOk4zOiCwTR?= Mmq3V2FPT0WU
COLO-684 M{LsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWD6dId3UUN3ME2yOk41OSCwTR?= NInB[ZBUSU6JRWK=
HuP-T4 M{nIXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTJ5LkOgcm0> NULDdGFuW0GQR1XS
SW837 NUfYTWFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTkTWM2OD1{Nz62NkBvVQ>? MUTTRW5ITVJ?
MDA-MB-231 Ml3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:wTWM2OD1{Nz63PEBvVQ>? MlH2V2FPT0WU
KYSE-140 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJ5LkmxJI5O NYnWVG5FW0GQR1XS
NOMO-1 M3Gzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;rTWM2OD1{OD62PEBvVQ>? MUXTRW5ITVJ?
GP5d M2Pkdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJ6LkeyJI5O M4\BR3NCVkeHUh?=
COR-L105 MmnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfTTWM2OD1{OT60NkBvVQ>? MXvTRW5ITVJ?
LS-411N MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[5TWM2OD1{OT64PEBvVQ>? NFrWdWdUSU6JRWK=
NY MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTNyLkG4JI5O NFHDU3BUSU6JRWK=
NCI-H2030 Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIL5S|RKSzVyPUOwMlQ2KG6P MXrTRW5ITVJ?
CCF-STTG1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTNzLkSyJI5O NYjWe4VJW0GQR1XS
NCI-H1703 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnZTWM2OD1|MT63PEBvVQ>? MYrTRW5ITVJ?
TUR NYLNbGxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml6yTWM2OD1|Mj6wN{BvVQ>? MWLTRW5ITVJ?
NOS-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHiTpBKSzVyPUOyMlQ1KG6P MWjTRW5ITVJ?
A2058 M2[xeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFyzPYpKSzVyPUOyMlg{KG6P NY\0O2NzW0GQR1XS
LCLC-103H NVvlSlY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGX6PHJKSzVyPUOzMlI2KG6P NVjlNJZzW0GQR1XS
NCI-H510A M{fJ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHpVHU6UUN3ME2zN{4zPyCwTR?= MUnTRW5ITVJ?
BC-1 NHXzNFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkO2TWM2OD1|Mz63O{BvVQ>? NVK0V5M{W0GQR1XS
SK-CO-1 M4K2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTN2LkCxJI5O M1jmT3NCVkeHUh?=
A673 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXuzdHBuUUN3ME2zOE4yPyCwTR?= Mkf1V2FPT0WU
VM-CUB-1 Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTN2Lk[5JI5O NFnXN5JUSU6JRWK=
HH NWrGOZpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDSTWM2OD1|NT6wOkBvVQ>? M3;sS3NCVkeHUh?=
CAL-27 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zzVmlEPTB;M{WuNVYhdk1? NHri[VZUSU6JRWK=
NEC8 M4WyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzZTWM2OD1|NT6zO{BvVQ>? Mo\DV2FPT0WU
BxPC-3 Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTN4LkmxJI5O M4SySHNCVkeHUh?=
SNB75 NV75VoN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIG0eXBKSzVyPUO3MlI1KG6P M3fTeXNCVkeHUh?=
NB13 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXqdoE2UUN3ME2zPE4zOyCwTR?= MYDTRW5ITVJ?
SK-OV-3 M4HXfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfKWFJMUUN3ME2zPE44PCCwTR?= M2TyOnNCVkeHUh?=
ME-180 MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rGRmlEPTB;M{iuPEBvVQ>? NV;zToE3W0GQR1XS
JiyoyeP-2003 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7STWM2OD1|OT6zPEBvVQ>? MVXTRW5ITVJ?
LU-134-A M1vlNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTTUFhKSzVyPUSwMlAzKG6P M3jTZ3NCVkeHUh?=
LS-123 M3HNZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTRyLkK4JI5O NXL3XoU5W0GQR1XS
COLO-800 M4K3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn23TWM2OD12MD61OkBvVQ>? Ml6yV2FPT0WU
LB831-BLC MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\TTWM2OD12MT64OUBvVQ>? Mlr5V2FPT0WU
NCI-H747 NIrndWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\HUGRmUUN3ME20Nk4zQCCwTR?= NV7tblNIW0GQR1XS
MZ7-mel M1naeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHe1S2lKSzVyPUSyMlY3KG6P Ml;jV2FPT0WU
GT3TKB MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTR{LkeyJI5O MVfTRW5ITVJ?
MOLT-16 M3zOUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn6boJKSzVyPUSzMlA2KG6P MUXTRW5ITVJ?
23132-87 NVvVV2JtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;5eo95UUN3ME20N{4xPSCwTR?= NWr2RWhoW0GQR1XS
PF-382 NGK4dmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLtbGR2UUN3ME20OE4zOiCwTR?= M3\3cnNCVkeHUh?=
ES3 NHfq[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;2TWM2OD12ND62JI5O NWrWeYtTW0GQR1XS
SW756 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPsO25KSzVyPUS1MlE1KG6P NELrTIpUSU6JRWK=

... Click to View More Cell Line Experimental Data

体内研究 在胰腺L3.6pl肿瘤转移的裸鼠中,Gemcitabine和C225联用导致生长抑制,肿瘤消退。Gemcitabine单独给药治疗减少了平均肿瘤体积,从538到152毫米。在Gemcitabine治疗的肿瘤中,Gemcitabine可以减少血管内皮生长因子和白细胞介素8的产生。[2] Gemcitabine是能够显著地和特异地减少骨髓抑制性细胞的数量,并不显著改变CD4(+)T细胞,CD8(+)T细胞,NK细胞,巨噬细胞,或B细胞的数量。[4] Gemcitabine和curcumin联用显著减少肿瘤体积(与对照组和单独Gemcitabine处理相比),Ki-67的增殖指数(与对照组相比),NF-κB的激活和表达NF-κB的调节基因产物(细胞周期蛋白D1,c-myc的和Bcl-2和Bcl-xL的细胞凋亡蛋白-1,环氧化酶-2,基质金属蛋白酶,和血管内皮生长因子的细胞抑制剂)。Gemcitabine和curcumin联用也抑制血管生成,以CD31(+)的微血管密度为标志。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
water (warmed)
52mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 263.2
化学式

C9H11F2N3O4

CAS号 95058-81-4
稳定性 powder
in solvent
别名 LY-188011, NSC 613327

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic December 1 2019 Phase 1|Phase 2
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic December 1 2019 Phase 1|Phase 2
NCT03865563 Not yet recruiting Pancreatic Adenocarcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins July 2019 Phase 1
NCT03697564 Not yet recruiting Pancreatic Cancer Stage IV Hitendra Patel|Stand Up To Cancer|Bristol-Myers Squibb|University of California San Diego July 2019 Phase 2
NCT03865563 Not yet recruiting Pancreatic Adenocarcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins July 2019 Phase 1
NCT03697564 Not yet recruiting Pancreatic Cancer Stage IV Hitendra Patel|Stand Up To Cancer|Bristol-Myers Squibb|University of California San Diego July 2019 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • 回答:

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

DNA/RNA Synthesis Signaling Pathway Map

相关DNA/RNA Synthesis产品

Tags: 购买Gemcitabine | Gemcitabine ic50 | Gemcitabine 价格 | Gemcitabine DMSO溶解度 | 采购Gemcitabine | Gemcitabine 生产 | Gemcitabine 小鼠 | Gemcitabine 化学结构 | Gemcitabine 分子量 | Gemcitabine molecular weight | Gemcitabine 说明书 | Gemcitabine 供应商 | Gemcitabine 体内 | Gemcitabine 细胞系 | Gemcitabine 浓度 | Gemcitabine nmr | Gemcitabine 核磁 | Gemcitabine 半数抑制浓度 | Gemcitabine 体外
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID